Validation of an Instrument to Measure Quality of Life in British Children With Inflammatory Bowel Disease

Ogden, C.A.*; Akobeng, A.K.; Abbott, J.*; Aggett, P.; Sood, M.R.; Thomas, A.G.

Journal of Pediatric Gastroenterology & Nutrition: September 2011 - Volume 53 - Issue 3 - p 280–286
doi: 10.1097/MPG.0b013e3182165d10
Original Articles: Gastroenterology

Objective: To validate IMPACT-III (UK), a health-related quality of life (HRQoL) instrument, in British children with inflammatory bowel disease (IBD).

Patients and Methods: One hundred six children and parents were invited to participate. IMPACT-III (UK) was validated by inspection by health professionals and children to assess face and content validity, factor analysis to determine optimum domain structure, use of Cronbach alpha coefficients to test internal reliability, ANOVA to assess discriminant validity, correlation with the Child Health Questionnaire to assess concurrent validity, and use of intraclass correlation coefficients to assess test-retest reliability. The independent samples t test was used to measure differences between sexes and age groups, and between paper and computerised versions of IMPACT-III (UK).

Results: IMPACT-III (UK) had good face and content validity. The most robust factor solution was a 5-domain structure: body image, embarrassment, energy, IBD symptoms, and worries/concerns about IBD, all of which demonstrated good internal reliability (α = 0.74–0.88). Discriminant validity was demonstrated by significant (*P < 0.05, **P < 0.01) differences in HRQoL scores between the severe, moderate, and inactive/mild symptom severity groups for the embarrassment scale (63.7* vs 81.0 vs 81.2), IBD symptom scale (45.0** vs 64.2* vs 80.6), and the energy scale (46.4* vs 62.1* vs 77.7). Concurrent validity of IMPACT-III (UK) with comparable domains of the Child Health Questionnaire was confirmed. Test-retest reliability was confirmed with good intraclass correlation coefficients of 0.66 to 0.84. Paper and computer versions of IMPACT-III (UK) collected comparable scores, and there were no differences between the sexes and age groups.

Conclusions: IMPACT-III (UK) appears to be a useful tool to measure HRQoL in British children with IBD.

*University of Central Lancashire, Preston

Royal Manchester Children's Hospital, Manchester

School of Medicine and Health, Lancaster University, Lancaster, UK.

Address correspondence and reprint requests to Dr A.G. Thomas, Royal Manchester Children's Hospital, Oxford Road, Manchester, M13 9WL, UK (e-mail: adrian.thomas@cmft.nhs.uk).

Received 27 March, 2010

Accepted 4 October, 2010

The authors report no conflicts of interest.

Copyright 2011 by ESPGHAN and NASPGHAN